- Trial Phase
- Phase 3 (pivotal)
- Time to Market
- Unknown; Phase 3 data expected H2 2026. If positive, FDA submission would follow, likely putting potential approval ~1-2 years out (2027-2028).
- Why 7/10
- The next hard, dated catalyst is the Phase 3 (LIVERATION, NCT05201404) topline overall-survival readout for Namodenoson in advanced HCC (Child-Pugh B7) — the trial's estimated completion date is October 31, 2026, with results expected in H2 2026. This pivotal readout on the company's lead asset drives most of Can-Fite's enterprise value, but the company also has a separate Phase 3 psoriasis program (Piclidenoson), so it is not a pure single-asset binary. Score of 7 reflects a major binary readout within ~4 months on a primary value driver.
The Phase 3 HCC readout (H2 2026) is the defining event for CANF. A positive result would validate the drug in a high-unmet-need niche (CPB7 patients) and could support an FDA filing given Fast Track/Orphan designations. However, the company had only ~$5.5M cash (mid-2025), a net loss of $9.83M in 2025, and executed a 1-for-3,000 reverse split in January 2026 — severe dilution risk before any commercial milestone. The stock trades at a micro-cap level (~$7-16M market cap) with very thin institutional ownership; any data catalyst could produce outsized moves in either direction.
Price Chart
Executive Summary
Namodenoson (CF102) is Can-Fite BioPharma's lead oral drug candidate — a selective A3 adenosine receptor agonist being developed for liver cancer (HCC), MASH, and pancreatic cancer. The pivotal Phase 3 HCC LIVERATION trial is the primary value driver, with an estimated completion date of October 31, 2026 and results expected in H2 2026. The drug targets a specific high-unmet-need population (CPB7 cirrhosis patients with advanced HCC, largely excluded from other trials) and has FDA Fast Track, FDA Orphan Drug, and EMA Orphan Drug designations for HCC. A Phase 2a pancreatic cancer study met its safety endpoint in March 2026, fueling recent stock momentum. However, Can-Fite is a micro-cap with limited cash (~$5.5M), ongoing net losses, and a recent 1-for-3,000 reverse split — severe financing risk. The HCC competitive landscape is crowded, but Namodenoson's unique niche and oral formulation offer differentiation if Phase 3 data are positive.
How It Works
Namodenoson is a small-molecule pill that selectively activates a specific receptor called the A3 adenosine receptor (A3AR). This receptor is found at abnormally high levels on the surface of cancer cells and inflamed liver cells, but not on healthy cells. By activating it, the drug triggers a chain of signals inside the cell that causes cancer cells to die (apoptosis) and reduces inflammation. It's like a key that only fits a lock found on sick cells, leaving normal cells alone — which is why it has shown a favorable safety/tolerability profile.
Trial Status
The pivotal Phase 3 LIVERATION trial (NCT05201404) is a randomized, double-blind, placebo-controlled study evaluating Namodenoson as a 2nd/3rd-line treatment in advanced hepatocellular carcinoma (HCC) patients with Child-Pugh Class B7 cirrhosis. The trial is enrolling in Israel, Europe, and the US. Estimated study completion is October 31, 2026 (CenterWatch), with prior primary completion listed as February 2026 (Guideline Central), suggesting data collection is finished and analysis is underway. The drug also completed a Phase 2a pancreatic cancer trial (March 2026) meeting its primary safety endpoint, with a Phase 2b study planned, and a Phase 2b MASH trial is active.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 HCC (LIVERATION) topline overall-survival results — expected H2 2026, estimated study completion October 31, 2026 (CenterWatch, GuidelineCentral).
- Phase 2b MASH trial data readout — timing not confirmed but listed as ongoing.
- Phase 2b pancreatic cancer study initiation — company plans to advance following Phase 2a safety success (Benzinga, July 1, 2026).
- Potential partnering/licensing announcements — company presented at BIO International Convention June 2026 seeking partnerships (Business Insider).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Can-Fite BioPharma Ltd. 6-K CANF ·Originating report